NANJING, CHINA, September 28, 2021 - MGI and AcornMed officially announced their cooperation on establishing the High-throughput Sequencing Innovation Application Demonstration Center of Precision Diagnosis and Treatment of Urinary Tract Cancers.

High-throughput sequencing will further promote the development of precision diagnosis and treatment of urinary tract cancers.

The establishment of the Innovation application Demonstration Center marks an important step forward to promote the implementation of the cooperation between MGI and AcornMed after the strategic cooperation reached on August 19 this year. Based on high-throughput sequencing technology, the two parties will jointly build the first innovative application demonstration center of Precision Diagnosis and Tumor Treatment in the greater Beijing-Tianjin-Hebei region (the Capital Economic Zone) to develop a one-stop platform of genetic testing for urinary tract cancers.

Empowered by MGISEQ-2000 high-throughput sequencing platforms, and AcornMed will provide more accurate, convenient, and higher quality services for genetic disease testing. Its establishment will help AcornMed enhance its sequencing data capacity and promote the application of artificial intelligence platform for precision medicine in accurate cancer diagnosis and screening.

High-throughput Sequencing Platform MGISEQ-2000

The morbidity and mortality of urothelial tumor, renal cell carcinoma and prostate cancer in China have been increasing year by year. While there has been a lack of effective means for the early diagnosis and postoperative tumor screening, making it difficult to conduct personalised treatment.

The development of high-throughput sequencing will provide the technological platform for precision medicine to assist clinical diagnosis and treatment.

High-throughput sequencing technology, also known as large-scale parallel sequencing (MPS), has the advantages of high throughput, low cost and high accuracy. It has been widely used in precision medicine, and has gradually become the mainstream technology for cancer genome sequencing services, including concomitant diagnosis, early cancer screening, prognosis management and R&D.

The in-depth cooperation of the two parties will promote the innovative development of industrial ecosystem.

MGI will continue to provide AcornMed with quality products and services to develope clinical testing products. Based on its technical strengths and forward-looking industrial strategies, MGI will empower more users and promote the innovative development of industrial ecosystem.